Clinical Trial Update: A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 safety study evaluating nivolumab in combination with ipilimumab for advanced non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: WITHDRAWN